利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

379 条记录 (耗时 0.051 秒)

    PHARMACEUTICAL COMPOUND
    62.
    发明公开
    PHARMACEUTICAL COMPOUND 审中-公开

    公开(公告)号：EP3349750A1

    公开(公告)日：2018-07-25

    申请号：EP16847099.5

    申请日：2016-09-12

    申请人： Iomet Pharma Ltd. ,  Merck Sharp & Dohme Corp.

    发明人： COWLEY, Phillip, M. ,  HAN, Yongxin

    IPC分类号： A61K31/404 ,  C07D209/30

    CPC分类号： C07D403/12 ,  A61K31/404 ,  A61K31/4155 ,  A61K45/06 ,  C07D209/30 ,  A61K2300/00

    摘要： Provided is a compound having formula (I): wherein R2 is selected from —C1, —Br and —CN; R1 and R4 are independently selected from H and —F; R631, R632, R641 and R642 are independently selected from —H, —F and substituted or unsubstituted C1-C3 alkyl groups; and R651 and R652 are independently selected from H and substituted or unsubstituted C1-C3 alkyl groups and substituted or unsubstituted phenyl groups; and wherein at least one of R631, R632, R641, R642 and R652 is not —H, or wherein when all of R631, R632, R641, R642 and R652 are —H, R651 is not Me or Et.

    RING-FUSED COMPOUND
    70.
    发明公开
    RING-FUSED COMPOUND 有权
    ANNELLIERTE VERBINDUNG

    公开(公告)号：EP2669270A1

    公开(公告)日：2013-12-04

    申请号：EP12739424.5

    申请日：2012-01-30

    申请人： Sato Pharmaceutical Co., Ltd.

    发明人： NAGAI Keita ,  NAGASAWA Koh ,  TAKAHASHI Hirobumi ,  BABA Motoaki ,  FUJIOKA Shinichi ,  KONDOH Eri ,  TANAKA Kenichi ,  ITOH Yoshiki

    IPC分类号： C07D209/08 ,  A61K31/404 ,  A61K31/416 ,  A61K31/4184 ,  A61K31/4439 ,  A61P9/10 ,  A61P13/04 ,  A61P13/12 ,  A61P19/02 ,  A61P19/06 ,  A61P43/00 ,  C07D209/30 ,  C07D231/56 ,  C07D235/08 ,  C07D235/10 ,  C07D401/06 ,  C07D405/06

    CPC分类号： C07D471/04 ,  C07D209/08 ,  C07D209/12 ,  C07D209/30 ,  C07D231/56 ,  C07D235/06 ,  C07D235/08 ,  C07D235/10 ,  C07D401/06 ,  C07D403/04 ,  C07D405/06 ,  C07D409/06 ,  C07D413/06

    摘要： The present invention relates to a compound that has URAT1 inhibitory action, and a URAT1 inhibitor, a blood uric acid level-reducing agent and a pharmaceutical composition comprising the compound. More specifically, the present invention relates to a compound represented by Formula (I) below.

    [in the formula,
    R 1 is -Q 1 -A 1 and the like; ---- is a double bond or a single bond; when ---- is a double bond, W 1 is a nitrogen atom or a group represented by the general formula: =C(R a )-, and W 2 is a nitrogen atom or a group represented by the general formula: =C(R b ) -; when ---- is a single bond, W 1 is a group represented by the general formula: -C(R aa )(R ab )- or a group represented by the general formula: -(C=O) -, and W 2 is a group represented by the general formula: C(R ba )(R bb )-, a group represented by the general formula: - (C=O) - or a group represented by the general formula: -N(R bc )-; W 3 , W 4 and W 5 are each independently a nitrogen atom or a methine group and the like that may have a substituent; X is a single bond, an oxygen atom and the like; Y is a single bond or (CR Yi R Yi' ) n ; and Z is a hydroxyl group or COOR 2 and the like.

    摘要翻译： 本发明涉及具有URAT1抑制作用的化合物和URAT1抑制剂，血液中尿酸水平降低剂和包含该化合物的药物组合物。 更具体地，本发明涉及由下式（I）表示的化合物。 [式中，R 1为-Q 1 -A 1等， ----是双重债券或单一债券; 当----是双键时，W 1是氮原子或由通式= C（R a） - 表示的基团，W 2是氮原子或由以下通式表示的基团：= C（R b） - ; 当----是单键时，W 1是由通式-C（R aa）（R ab） - 或由通式表示的基团 - （C = O） - 表示的基团，和 W 2是由通式C（R ba）（R bb） - 表示的基团，由以下通式表示的基团： - （C = O） - 或由通式-N（R bc） - ; W 3，W 4和W 5各自独立地为可以具有取代基的氮原子或次甲基等; X是单键，氧原子等; Y是单键或（CR Yi R Yi'）n; Z为羟基或COOR 2等。